Role of the immune response in BCG for bladder cancer - PubMed

Review

Role of the immune response in BCG for bladder cancer

T L Ratliff. Eur Urol. 1992.

Abstract

Intravesical bacillus Calmette-Guérin (BCG) has been shown in prospective, randomized clinical trials to be the treatment of choice for superficial bladder cancer. In this treatment regimen, viable bacteria are introduced into the bladder, provoking an infection which induces the immunological response that initiates antitumour activity. The role of T-lymphocytes and the T-lymphocyte subsets, helper T cells (Th) and cytotoxic T-cells (Tc) in the antitumour response has been evaluated. Depletion of total T, Th or Tc subsets in mice eliminated BCG-mediated antitumour activity. Delayed type hypersensitivity was abrogated only in Th-depleted mice, but the presence of Th-mediated delayed-type hypersensitivity (DTH) was not sufficient for expression of BCG-mediated antitumour activity. There was no evidence for the induction of protective immunity to the tumour after BCG therapy. These results show that T-lymphocytes are required for BCG-mediated antitumour activity and suggest that the antitumour activity mediated by BCG is of a nonspecific immunological type. No specific tumour cell immunity was detected.

Similar articles

• Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

  Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O'Donnell MA, Ratliff TL. Nadler R, et al. Clin Exp Immunol. 2003 Feb;131(2):206-16. doi: 10.1046/j.1365-2249.2003.02071.x. Clin Exp Immunol. 2003. PMID: 12562379 Free PMC article.

• T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.

  Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. Ratliff TL, et al. J Urol. 1993 Sep;150(3):1018-23. doi: 10.1016/s0022-5347(17)35678-1. J Urol. 1993. PMID: 8102183

• Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.

  van der Meijden AP, Steerenberg PA, van Hoogstraaten IM, Kerckhaert JA, Schreinemachers LM, Harthoorn-Lasthuizen EJ, Hagenaars AM, de Jong WH, Debruijne FM, Ruitenberg EJ. van der Meijden AP, et al. Cancer Immunol Immunother. 1989;28(4):287-95. doi: 10.1007/BF00205239. Cancer Immunol Immunother. 1989. PMID: 2784716 Free PMC article.

• Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.

  Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K. Prescott S, et al. Clin Infect Dis. 2000 Sep;31 Suppl 3:S91-3. doi: 10.1086/314066. Clin Infect Dis. 2000. PMID: 11010831 Review.

• Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin.

  Liu X, Dowell AC, Patel P, Viney RP, Foster MC, Porfiri E, James ND, Bryan RT. Liu X, et al. Future Oncol. 2014 Jun;10(8):1443-56. doi: 10.2217/fon.14.79. Future Oncol. 2014. PMID: 25052754 Review.

Cited by

• Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity.

  Luo Y, Chen X, Han R, O'Donnell MA. Luo Y, et al. Clin Exp Immunol. 2001 Feb;123(2):264-70. doi: 10.1046/j.1365-2249.2001.01428.x. Clin Exp Immunol. 2001. PMID: 11207657 Free PMC article.

• Interferon-gamma Added During Bacillus Calmette-Guerin Induced Dendritic Cell Maturation Stimulates Potent Th1 Immune Responses.

  Shankar G, Pestano LA, Bosch ML. Shankar G, et al. J Transl Med. 2003 Oct 10;1(1):7. doi: 10.1186/1479-5876-1-7. J Transl Med. 2003. PMID: 14580262 Free PMC article.

• Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

  Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O'Donnell MA, Ratliff TL. Nadler R, et al. Clin Exp Immunol. 2003 Feb;131(2):206-16. doi: 10.1046/j.1365-2249.2003.02071.x. Clin Exp Immunol. 2003. PMID: 12562379 Free PMC article.

• Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells.

  Coon BG, Crist S, González-Bonet AM, Kim HK, Sowa J, Thompson DH, Ratliff TL, Aguilar RC. Coon BG, et al. Int J Cancer. 2012 Aug 1;131(3):591-600. doi: 10.1002/ijc.26413. Epub 2011 Oct 20. Int J Cancer. 2012. PMID: 21901746 Free PMC article.

• A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein.

  Luo Y, Szilvasi A, Chen X, DeWolf WC, O'Donnell MA. Luo Y, et al. Clin Diagn Lab Immunol. 1996 Nov;3(6):761-8. doi: 10.1128/cdli.3.6.761-768.1996. Clin Diagn Lab Immunol. 1996. PMID: 8914772 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information